10-QPeriod: Q1 FY2024

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 2024

Filed April 25, 2024For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb (BMY) reported its first-quarter 2024 financial results, revealing a mixed performance with continued strategic evolution. The company saw a decline in revenue year-over-year, largely attributed to key product headwinds and a strategic pivot towards new growth drivers. Despite revenue challenges, BMY demonstrated effective cost management and a strong commitment to research and development, which are crucial for its long-term pipeline success. Investors should closely monitor the progress of its newly launched products and pipeline advancements, as these will be critical for offsetting patent expirations and driving future top-line growth. The company's cash flow generation remains robust, supporting its ongoing investment in R&D and potential strategic acquisitions.

Financial Highlights

57 data points
Beta

Revenue

$11.87B

75.3% Gross Margin

Net Income

-$11.91B

-100.4% Net Margin

EPS (Diluted)

$-5.89

Total Assets

$99.03B

Cash & Equivalents

$9.33B

Free Cash Flow

$2.55B

Financial Statements
Beta
Revenue$11.87B
Cost of Revenue$2.93B
Gross Profit$8.93B
R&D Expenses$2.69B
SG&A Expenses$2.37B
Operating Expenses$23.38B
Interest Expense$425.00M
Net Income-$11.91B
EPS (Basic)$-5.89
EPS (Diluted)$-5.89
Shares Outstanding (Basic)2.02B
Shares Outstanding (Diluted)2.02B

Key Highlights

  • 1Revenue for the first quarter of 2024 decreased compared to the prior year, reflecting ongoing challenges with established products and patent expirations.
  • 2The company continues to invest heavily in Research and Development, underscoring its commitment to innovation and future growth drivers.
  • 3Bristol Myers Squibb is actively managing its product portfolio and strategic direction to adapt to market dynamics and upcoming patent cliffs.
  • 4Cash flow from operations remains a strength, providing flexibility for R&D, debt repayment, and potential business development activities.
  • 5The filing provides updates on legal proceedings and risk factors, important considerations for assessing the company's operational and regulatory landscape.
  • 6Management's Discussion and Analysis offers insights into the company's performance drivers, strategic initiatives, and outlook.

Frequently Asked Questions

The revenue decline is primarily attributed to ongoing headwinds from key established products, including the impact of loss of exclusivity for certain older drugs, and the company's strategic shift to focus on newer, higher-growth therapeutics.

Bristol Myers Squibb is actively pursuing a strategy centered on developing and launching new, innovative medicines. This includes significant investment in its R&D pipeline, focusing on therapeutic areas with high unmet needs, and potentially pursuing strategic acquisitions or partnerships to bolster its portfolio.

The company's cash flow from operations remains strong, which is a positive indicator of its underlying business health. This robust cash generation provides the company with the financial flexibility to fund its extensive R&D efforts, manage its debt, and explore strategic growth opportunities.

Key risks typically include challenges in drug development and clinical trials, regulatory approvals, market competition, pricing pressures, patent expirations, and the success of new product launches. Specific details are elaborated within the 'Risk Factors' section of the filing.